| HOME >> BIOLOGY >> TECHNOLOGY |
WASHINGTON, March 4 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that Vijay Samant, the company's President and Chief Executive Officer, will participate in a roundtable discussion, "An Industry Call to Action: Challenges and Opportunities for Engaging in Global Health Product Development," and present an overview of the company's programs addressing pressing global health needs on Tuesday, March 11, at the Biotechnology Industry Organization (BIO) and BIO Ventures for Global Health (BVGH) conference, "Partnering for Global Health Forum 2008," (Washington -- March 11-12). The forum is sponsored by BIO, BVGH and the Bill & Melinda Gates Foundation.
About BVGH
BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for neglected diseases of the developing world. Our mission is to break down barriers that hinder industry involvement in global health product development and to catalyze new industry investment. Additional information on BVGH is available at http://www.bvgh.org.
About BIO
BIO represents more than 1,150 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Additional information on BIO is available at http://www.bio.org.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contact: Alan R. Engbring
(858) 646-1127
Website: http://www.vical.com
'/>"/>
| SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
2. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
3. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
4. Vical Launches Redesigned Website
5. Vical Presentation at Military Pandemic Influenza Workshop
6. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
7. Vical to Present at Investor Conferences
8. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
9. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
10. Nventa updates progress of cervical dysplasia trial with new HspE7
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |